Condition: Refractory Malignant Solid Neoplasm · Osteosarcoma · Leiomyosarcomas · Sponsor: City of Hope Medical Center
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Vincent Chung, MD · 6262184673 · vchung@coh.org
Always discuss trial participation with your own doctor first.
| Honor Health Research and Innovation Institute | Scottsdale, Arizona, United States | Not Yet Recruiting |
| City of Hope Medical Center | Duarte, California, United States | Recruiting |
| City of Hope at Long Beach Elm | Long Beach, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05227326